Dermata: XYNGARI Phase 3 STAR-1 acne trial meets co-primary endpoints; cash $9.7M

Dermata Therapeutics, Inc.

XYNGARI Phase 3 STAR-1 achieved statistically significant results on all co-primary endpoints at all time points vs placebo.
Entered clinical trial collaboration with Revance to study DMT410 with DAXXIFY for axillary hyperhidrosis.
Raised $8.8M gross proceeds from private placement and warrant inducement financings in Q1 2025.
Cash and equivalents $9.7M as of March 31, 2025, up from $3.2M; expected to fund operations into Q1 2026.
R&D expenses $1.3M, G&A $1.1M; operating cash burn $1.9M in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.